Health and Healthcare
Is This the Beginning of the End for Tonix Pharma?
Published:
Last Updated:
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) led bears in Tuesday’s trading session following the release of top-line results from a Phase 2 clinical study. Basically, the company announced top-line results for its proof-of-concept clinical study of TNX-201 (dexisometheptene mucate) in episodic tension-type headache.
Needless to say, investors were not happy with these results. In 2016 alone, this stock has taken a beating, and unless this company can turn itself around in the near future, it could be the end.
Looking at the preliminary analysis of the results, Tonix determined that the study did not achieve its primary efficacy endpoint of participants achieving headache pain-free status at two hours after dosing.
At the same time, the study also did not achieve two other primary endpoints, which were the proportion of participants with at least a 70% reduction in pain from baseline on the Visual Analog Scale (VAS) at two hours after dosing, and an increase of the mean change from baseline to two hours post-dose in the VAS score.
On somewhat of a positive note, no serious adverse events were reported throughout the duration of the study. There were no treatment emergent adverse event categories reported by more than one participant (1.4%) in either treatment group during the double-blinded treatment period.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
